Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Cancer Immunol Immunother ; 72(12): 4457-4470, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37796299

RESUMO

BACKGROUND: The inducible Kras/p53 lung adenocarcinoma mouse model, which faithfully recapitulates human disease, is routinely initiated by the intratracheal instillation of a virus-based Cre recombinase delivery system. Handling virus-based delivery systems requires elevated biosafety levels, e.g., biosafety level 2 (BSL-2). However, in experimental animal research facilities, following exposure to viral vectors in a BSL-2 environment, rodents may not be reclassified to BSL-1 according to standard practice, preventing access to small animal micro-computed tomography (micro-CT) scanners that are typically housed in general access areas such as BSL-1 rooms. Therefore, our goal was to adapt the protocol so that the Cre-induced KP mouse model could be handled under BSL-1 conditions during the entire procedure. RESULTS: The Kras-Lox-STOP-Lox-G12D/p53 flox/flox (KP)-based lung adenocarcinoma mouse model was activated by intratracheal instillation of either an adenoviral-based or a gutless, adeno-associated viral-based Cre delivery system. Tumor growth was monitored over time by micro-CT. We have successfully substituted the virus-based Cre delivery system with a commercially available, gutless, adeno-associated, Cre-expressing vector that allows the KP mouse model to be handled and imaged in a BSL-1 facility. By optimizing the anesthesia protocol and switching to a microscope-guided vector instillation procedure, productivity was increased and procedure-related complications were significantly reduced. In addition, repeated micro-CT analysis of individual animals allowed us to monitor tumor growth longitudinally, dramatically reducing the number of animals required per experiment. Finally, we documented the evolution of tumor volume for different doses, which revealed that individual tumor nodules induced by low-titer AAV-Cre transductions can be monitored over time by micro-CT. CONCLUSION: Modifications to the anesthesia and instillation protocols increased the productivity of the original KP protocol. In addition, the switch to a gutless, adeno-associated, Cre-expressing vector allowed longitudinal monitoring of tumor growth under BSL-1 conditions, significantly reducing the number of animals required for an experiment, in line with the 3R principles.


Assuntos
Adenocarcinoma de Pulmão , Neoplasias Pulmonares , Camundongos , Animais , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patologia , Proteínas Proto-Oncogênicas p21(ras)/genética , Dependovirus/genética , Microtomografia por Raio-X , Proteína Supressora de Tumor p53 , Contenção de Riscos Biológicos , Modelos Animais de Doenças , Vetores Genéticos/genética
2.
Methods Mol Biol ; 1745: 67-82, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29476463

RESUMO

Mass cytometry (cytometry by time-of-flight, CyTOF) is a high-dimensional single-cell analytical technology that allows for highly multiplexed measurements of protein or nucleic acid abundances by bringing together the detection capacity of atomic mass spectroscopy and the sample preparation workflow typical of regular flow cytometry. In 2014 the mass cytometer was adapted for the acquisition of samples from microscopy slides (termed imaging mass cytometry), greatly increasing the applicability of this technology with the inclusion of spatial information. By using antibodies (or other probes) labeled with purified metal isotopes, mass cytometers are currently able to detect more than 50 different parameters at a single-cell level, exceeding the dimensionality of any other flow cytometry methodology currently on the market. This capability licenses unprecedented possibilities in many areas dealing with complex cellular mixtures (immunology, cell biology, and beyond), improving biomarker discovery and moving us closer to affordable personalized medicine than before.


Assuntos
Citometria de Fluxo/métodos , Imunofenotipagem/métodos , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo , Biomarcadores , Técnicas de Cultura de Células , Separação Celular , Análise de Dados , Humanos , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/metabolismo , Análise de Célula Única
3.
Curr Protoc Immunol ; 118: 5.11.1-5.11.25, 2017 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-28762483

RESUMO

Mass cytometry is an analytical technology that combines the sample preparation workflow typical of flow cytometry and the detection capacity of atomic mass spectroscopy, allowing for highly multiplexed measurements of protein or nucleic acid targets on single cells. In 2014, the mass cytometer was adapted for the acquisition of samples from microscopy slides (termed imaging mass cytometry), greatly increasing the applicability of this technology. By using antibodies (or other probes) labeled with purified metal isotopes, the mass cytometer is able to detect up to 50 different parameters (current practical limit) at the single-cell level, enabling a deep and thorough profiling of individual cells in terms of their cell surface protein phenotype, physiological state, proliferation potential, and many other cell states or features. © 2017 by John Wiley & Sons, Inc.


Assuntos
Citometria de Fluxo/métodos , Análise de Célula Única/métodos , Anticorpos/imunologia , Citocinas/imunologia , Citometria de Fluxo/instrumentação , Humanos , Imunofenotipagem , Leucócitos Mononucleares/citologia , Leucócitos Mononucleares/imunologia , Análise de Célula Única/instrumentação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA